5-异丙氧基-1H-吡咯-3-胺 | 121507-34-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-异丙氧基-1H-吡咯-3-胺
• 中文别名: 5-异丙氧基-1H-吡唑-3-胺
• 英文名称: 5-propan-2-yloxy-1H-pyrazol-3-amine
• 英文别名: 5-isopropoxy-1H-pyrazol-3-amine；3-propan-2-yloxy-1H-pyrazol-5-amine
• CAS: 121507-34-4
• 化学式: C₆H₁₁N₃O
• mdl: MFCD11846994
• 分子量: 141.173
• InChiKey: BAYGRDORJOSALU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-异丙氧基-1H-吡咯-3-胺 在 10% Pd/C 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 乙腈 、 正丁醇 为溶剂， 反应 32.0h， 生成 N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-3-(5-isopropoxy-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine
  参考文献：
  名称：

  Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors

  摘要：

  Trk receptor tyrosine kinases have been implicated in cancer and pain. A crystal structure of TrkA with AZ-23 (1a) was obtained, and scaffold hopping resulted in two 5/6-bicyclic series comprising either imidazo[4,5-b]pyridines or purines. Further optimization of these two fusion series led to compounds with subnanomolar potencies against TrkA kinase in cellular assays. Antitumor effects in a TrkA-driven mouse allograft model were demonstrated with compounds 2d and 3a.

  DOI：

  10.1021/ml300074j
• 作为产物：
  描述：

  3-氨基-5-吡唑醇 生成 5-异丙氧基-1H-吡咯-3-胺
  参考文献：
  名称：

  WO2008135785A1

  摘要：

  公开号：

文献信息

• [EN] RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE RAF KINASES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011025951A1

  公开（公告）日：2011-03-03

  Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式(I)的化合物对于抑制Raf激酶很有用。本文揭示了利用式(I)的化合物及其立体异构体、互变异构体和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这类疾病，或相关病理条件的方法。
• Novel Compounds
  申请人：Theoclitou Maria-Elena

  公开号：US20080004302A1

  公开（公告）日：2008-01-03

  There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

  提供了一个化合物，其化学式为(I)：制备方法、药物组合物以及在治疗中的用途。
• An Approach for the Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidines via Cu(II)-Catalyzed [3+3] Annulation of Saturated Ketones with Aminopyrazoles
  作者：Jian Ren、Shihua Ding、Xiaonian Li、Ran Bi、Qinshi Zhao

  DOI：10.1021/acs.joc.1c01343

  日期：2021.9.17

  A one-step synthesis of diversely substituted pyrazolo[1,5-a]pyrimidines from saturated ketones and 3-aminopyrazoles is presented. This transformation involves the in situ formation of α,β-unsaturated ketones via a radical process, followed by [3+3] annulation with 3-aminopyrazoles in one pot. Mechanistic studies have shown that the dual C(sp3)–H bond functionalization of inactive ketones is required

  提出了从饱和酮和 3-氨基吡唑一步合成不同取代的吡唑并[1,5- a ]嘧啶。这种转化涉及通过自由基过程原位形成 α,β-不饱和酮，然后在一个锅中与 3-氨基吡唑进行 [3+3] 环化。机理研究表明，形成标题化合物需要非活性酮的双 C(sp 3 )-H 键官能化。值得注意的是，这种脱氢偶联过程提供了从市售底物获得大量具有抗肿瘤潜力的官能化吡唑并[1,5- a ]嘧啶的途径。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Zhang Jiazhong

  公开号：US20110263595A1

  公开（公告）日：2011-10-27

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, global ischemia, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metasteses, gastrointestinal stromal tumors, and giant cell tumors.

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对Fms、Kit、Flt3、TrkA、TrkB和TrkC激酶蛋白中的一个或多个具有活性。还描述了使用方法，用于治疗与Fms、Kit、Flt3、TrkA、TrkB和TrkC中的一个或多个活性相关的疾病和症状，包括类风湿性关节炎、骨关节炎、骨质疏松症、周围假体周围骨溶解、系统性硬化、脱髓鞘疾病、多发性硬化症、沙科特-玛丽-屈氏综合征、肌萎缩性侧索硬化、阿尔茨海默病、帕金森病、全球性缺血、溃疡性结肠炎、克罗恩病、免疫性血小板减少性紫癜、动脉粥样硬化、系统性红斑狼疮、自体移植的骨髓准备、移植排斥、肾小球肾炎、间质性肾炎、狼疮性肾炎、肾小管坏死、糖尿病性肾病、肾肥大、I型糖尿病、急性疼痛、炎症性疼痛、神经病性疼痛、急性髓样白血病、黑色素瘤、多发性骨髓瘤、乳腺癌、前列腺癌、胰腺癌、肺癌、卵巢癌、胶质瘤、胶质母细胞瘤、神经纤维瘤病、骨转移性溶骨病、脑转移瘤、胃肠道间质瘤和巨细胞瘤。
• TRK INHIBITION
  申请人：NantBio, Inc.

  公开号：US20180346451A1

  公开（公告）日：2018-12-06

  The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及使用取代嘧啶衍生物来调节肌球蛋白相关激酶（Trk）家族蛋白激酶，并且使用这些取代嘧啶衍生物来治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、牛皮癣、血栓形成、与失髓鞘或脱髓鞘相关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA异常活动相关的疾病或紊乱。